Rain Oncology Inc. (Nasdaq: RAIN), relating to its proposed sale to Pathos AI Inc. Under the terms of the agreement, RAIN shareholders are expected to receive $1.16 in cash plus one non-tradable CVR worth up to $0.17 per share they own
Rain Oncology Inc. (Nasdaq: RAIN), relating to its proposed sale to Pathos AI Inc. Under the terms of the agreement, RAIN shareholders are expected to receive $1.16 in cash plus one non-tradable CVR worth up to $0.17 per share they own